BMS-214662 (mesylate)
BMS-214662 mesylate is a potent and selective farnesyl transferase inhibitor with an IC50 of 1.35 nM. BMS-214662 mesylate exhibits potent antitumor activity and can be utilized in cancer research[1].
Product Specifications
CAS Number
474010-58-7
UNSPSC
12352005
Target
Farnesyl Transferase
Related Pathways
Metabolic Enzyme/Protease
Field of Research
Cancer
Smiles
CS(=O)(O)=O.O=S(N(CC1=CC(C#N)=CC=C1N(C2)CC3=CN=CN3)[C@@H]2CC4=CC=CC=C4)(C5=CC=CS5)=O
Molecular Formula
C26H27N5O5S3
Molecular Weight
585.72
References & Citations
[1]Hunt JT, et al. Discovery of (R) -7-cyano-2,3,4, 5-tetrahydro-1- (1H-imidazol-4-ylmethyl) -3- (phenylmethyl) -4- (2-thienylsulfonyl) -1H-1,4-benzodiazepine (BMS-214662), a farnesyltransferase inhibitor with potent preclinical antitumor activity. J Med Chem. 2000 Oct 5;43 (20) :3587-95.|[2]Rose WC, et al. Preclinical antitumor activity of BMS-214662, a highly apoptotic and novel farnesyltransferase inhibitor. Cancer Res. 2001 Oct 15;61 (20) :7507-17.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
Phase 1
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
M3887-10K-ML490 100 µL
MHC Class 2, D, DP (DMA, DMB, DP beta 1, DPB1, DRB, HLA Class II Histocompatibility Antigen DM beta Chain, HLA DMB, HLADM, HLADPB1, Major Histocompatibility Complex Class II (DP beta 1), MHC Class II Antigen DMB, MHC DPB1, RING6, RING7) (MaxLight 490) discontinued
Sign In for Pricing
View Details 
MBS8574973-01 0.1 mg
SARS-CoV-2 Nucleocapsid Phosphoprotein (N Protein) Polyclonal Antibody
Sign In for Pricing
View Details MBS8574973-02 5x 0.1 mg
SARS-CoV-2 Nucleocapsid Phosphoprotein (N Protein) Polyclonal Antibody
Sign In for Pricing
View Details 